A pharmaceutical manufacturer that is part of the Sovaldi drugmaker consortium is raising a significant amount of money via a crowdfunding platform.
The company, Aventis Pharmaceuticals, is working with investors including Google Ventures, Andreessen Horowitz and Union Square Ventures to raise $250 million.
Aventis is also seeking to raise a minimum of $200 million from a number of different investors, according to the company’s website.
The company is also developing a novel approach to manufacturing CSL drugs.
Aventes is using a novel, proprietary process called bioelectrical synthesis to produce its own CSL drug.
The Bioelectrical Synthesis process, or BES for short, involves the creation of an artificial molecule that is made from a small amount of biological material, called the precursor material.
The precursor is then purified by a process called electrochemical separation, which is known to produce CSL products.
Bioelectrical separation is the process used by Aventias Bioelectronic Solution Co., Ltd., which is based in Shizuoka, Japan.
It has raised $2.5 billion from a variety of sources including Microsoft Ventures, Bancor, Accel Partners and Fidelity Investments.
Avenuees has been developing a variety, including an anti-cancer drug, an antiemetic and a bronchodilator.
The pharmaceutical company also recently announced it is acquiring a medical device company called MuroTech.
It acquired Murotech for $1.5 million.
“The Bioelectric Synthesis business is the most challenging business to build a company around,” said David V. Mazer, chairman and chief executive officer of Aventus Pharmaceuticals.
“Our team is committed to doing whatever it takes to scale up to scale the market.”
The company’s bioelectronic manufacturing technology, however, could also lead to other drug developments.
A Ventis Bioelectric Solution Co. subsidiary, BioCure, has been working with biotech company Biogen Inc. to develop an immunotherapy drug that is designed to treat an infection that affects the immune system.
BioCure is also testing a treatment that is similar to a chemotherapy drug in a patient with type 2 diabetes.
It is also working on developing a new skin-appearing treatment for the treatment of psoriasis.
“We’re also building a new business that could create an incredible product pipeline,” Mazer said.
“This could be the most significant breakthrough we’ve ever made.”SOURCE Medical News Now, Aetna article